EcoDrugPlus

Neuromedin-K Receptor-Like

Ensembl ID : ENSDCDG00000027552
Gene Symbol: LOC114789239
3 Cross references
198 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-4-Like

Ensembl ID : ENSDCDG00000022388
Gene Symbol: LOC114783487
3 Cross references
191 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-4-Like

Ensembl ID : ENSDCDG00000023975
Gene Symbol: LOC114798748
3 Cross references
191 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSDCDG00000020237
Gene Symbol: LOC114766894
2 Cross references
186 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSDCDG00000021034
Gene Symbol: LOC114765869
3 Cross references
208 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Beta-4-Like

Ensembl ID : ENSDCDG00000023419
Gene Symbol: LOC114772170
2 Cross references
193 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSDCDG00000005481
Gene Symbol: NPY2R
3 Cross references
183 Possible Orthologues:

Neuropeptide Y Receptor Type 2-Like

Ensembl ID : ENSDCDG00000011287
Gene Symbol: LOC114794551
3 Cross references
178 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSDCDG00000035355
Gene Symbol: NTSR1
3 Cross references
133 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSDCDG00000014529
Gene Symbol: NTSR1
3 Cross references
199 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSDCDG00000010895
Gene Symbol: NTRK2
3 Cross references
137 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSDCDG00000021018
Gene Symbol: NTRK3
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).